Do idebenone and
vitamin therapy shorten the time to achieve visual recovery in Leber
hereditary optic neuropathy?
Mashima Y, Kigasawa K, Wakakura M, Oguchi Y.
Department of Ophthalmology,
Keio University School of Medicine, Tokyo, Japan.
J Neuroophthalmol 2000 Sep;20(3):166-70
ABSTRACT
OBJECTIVES: The authors investigated the effectiveness of idebenone combined
with vitamin B2 and vitamin C in the treatment of patients with Leber
hereditary optic neuropathy (LHON) in an early stage as compared with
untreated patients with LHON. These agents may stimulate the formation of ATP.
MATERIALS AND METHODS: For this retrospective study, the authors selected 28
outpatients with LHON from the Keio University Hospital. These patients were
followed for 2 to 19 years from disease onset. They were divided into two
groups: 14 untreated patients (11778 mutation in 10 patients, 3460 mutation in
2 patients, and 14484 mutation in 2 two patients); and 14 treated patients
(11778 mutation in 11 patients, 3460 mutation in 1 patient, and 14484 mutation
in 2 patients). The treated patients were administered medical treatment with
idebenone, vitamin B2, and vitamin C for at least 1 year. The current study
evaluated the following:
1) number of eyes with visual recovery > or = 0.3;
2) interval between the onset of LHON and the beginning of visual recovery;
3)
interval between the onset of LHON and visual recovery to 0.3; and 4) interval
between the beginning of medical treatment and the beginning of visual
recovery in the treated subjects.
RESULTS: There was no significant difference
in the number of eyes with visual recovery > or = 0.3 in the two groups
with the 3460, 11778, or 14484 mutation. Patients with visual recovery showed
a fenestrated scotoma or a clearing of central vision. The mean interval
between the onset of LHON and the beginning of visual recovery was
significantly shorter in the treated group (11.1 months) than in the untreated
group (17.4 months) (P = 0.03). The mean interval between the onset of LHON
and visual recovery to 0.3 was significantly shorter in the treated group
(17.6 months) than in the untreated group (34.4 months) (P = 0.01). The mean
interval between the initiation of medical treatment to the beginning of
visual recovery was 5.4 months.
CONCLUSIONS: Results suggest that the
administration of idebenone, vitamin B2, and vitamin C sped the recovery of
vision in patients with Leber
hereditary optic neuropathy.
Idebenone
- the ultimate anti-aging drug. (article)
Alzheimer's disease
Idebenone in
the treatment of Alzheimer's disease
Idebenone
efficacy of idebenone in the treatment of Alzheimer's
disease
Idebenone
Nerve Growth Factor synthesis stimulators in Alzheimer's
disease
Idebenone
in the treatment of dementia of the Alzheimer type
Idebenone
cognitive enhancement therapy for Alzheimer's
disease
MELAS
Idebenone
improves cerebral mitochondrial oxidative metabolism in MELAS
Idebenone
in young patients with mitochondrial encephalomyopathy (MELAS)
Idebenone
therapy in Mitochondrial encephalomyopathy (MELAS)
Idebenone
and Mitochondrial encephalomyopathy (MELAS)
Idebenone
successful therapy with idebenone in Mitochondrial
encephalomyopathy (MELAS)
.
Cardiomyopathy
Idebenone
improvement in mitochondrial cardiomyopathy following
treatment with idebenone
Idebenone
effect of idebenone on
cardiomyopathy in Friedreich's ataxia
.
Leber hereditary optic neuropathy (LHON)
Idebenone
does it shorten the time to visual recovery in Leber hereditary optic
neuropathy?
Idebenone
improvement in a patient with Leber's hereditary optic neuropathy (LHON)
Misc.
Idebenone
use in age-related cognitive disorders
Idebenone
protects hippocampal neurons against beta amyloid neurotoxicity
Idebenone
functions as a potent protective
hepatocyte antioxidant
Idebenone
neuroprotective effects of
idebenone can be attributed to its antioxidant ability
Idebenone
inhibition of brain mitochondrial
swelling
Idebenone
suppression of cold ischemia/reperfusion
injury of liver endothelium
Idebenone
ability to eliminate a nitroxide
radical in the rat
Idebenone
interaction with respiratory complexes of heart
mitochondria
Idebenone
effect on serotonin release and seroton receptors in rats
Idebenone
protects hepatic microsomes against damage in organ preservation solutions
Idebenone
protects against toxicity
induced by low density lipoprotein
Idebenone
protects against disorders due to cerebral hypoxia or
ischemia
Idebenone
protects against toxicity induced by low density
lipoprotein
Idebenone
attenuates neuronal degeneration induced by excitotoxins
Idebenone
augments long-term potentiation in
hippocampal slices in the guinea pig
Idebenoneeffects
on lipid peroxidation
in erythrocytes of stroke-prone, hypertensive rats
Idebenone
brain distribution and its effect on local cerebral
glucose utilization in rats
Idebenone
effects
on acetylcholine levels
in the brains of rats with cerebral ischemia
Idebenone
protective effect of idebenone against hypoxia in mice
Idebenone
improves learning and memory impairment induced in rats
Idebenone
effects
of idebenone on
neurological deficits in stroke-prone rats
Idebenone
effects
on memory induced impairment in rats
Idebenone
effects of idebenone on cerebral blood flow in rats with cerebral ischemia
Idebenone
inhibition
of brain mitochondrial swelling by idebenone
Idebenone
inhibition of platelet aggregation by
idebenone
Idebenone
effects of idebenone on monoamine metabolites of patients
with dementia
Idebenone
effects of idebenone on
metabolism of monoamines and cyclic AMP formation
Idebenone effects
on impairment of radial maze learning in cerebral embolized rats
Idebenone
effect of idebenone on lipid peroxidation in rat
brain homogenate
Idebenone
effects on muricidal behavior in rats with raphe
lesions
Idebenone inhibitory effect of idebenone on vascular lesions in
hypertensive rats
